Keyword Analysis & Research: imdevimab
Keyword Research: People who searched imdevimab also searched
Search Results related to imdevimab on Search Engine
-
Casirivimab/imdevimab - Wikipedia
https://en.m.wikipedia.org/wiki/Casirivimab/imdevimab
WEBCasirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection.
DA: 65 PA: 42 MOZ Rank: 47
-
FDA authorizes REGEN-COV mAb for prevention for COVID-19
https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19
WEBThe U.S. Food and Drug Administration today revised the emergency use authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together) authorizing REGEN-COV for emergency...
DA: 14 PA: 60 MOZ Rank: 47
-
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal …
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
WEBCasirivimab and imdevimab are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of casirivimab and imdevimab treatment...
DA: 49 PA: 79 MOZ Rank: 19
-
REGEN-COV Antibody Combination and Outcomes in Outpatients …
https://www.nejm.org/doi/full/10.1056/NEJMoa2108163
WEBSep 29, 2021 · In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients...
DA: 66 PA: 60 MOZ Rank: 32
-
Imdevimab - StatPearls - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK572065/
WEBJan 30, 2023 · Imdevimab is a monoclonal antibody (mAb) against spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (COVID-19). It is one of the SARS-CoV-2 neutralizing antibodies proposed for use in the clinical management of COVID-19. On 21st November 2020, imdevimab and casirivimab cocktail ...
DA: 21 PA: 14 MOZ Rank: 32
-
Casirivimab/Imdevimab: First Approval - PMC - National Center …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556815/
WEBOct 30, 2021 · Casirivimab/imdevimab received its first emergency use authorization for the treatment of COVID-19 in November 2020 in the USA, with similar authorizations subsequently granted in various other countries, including India, Canada, and Switzerland.
DA: 81 PA: 22 MOZ Rank: 34
-
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid …
https://www.nejm.org/doi/full/10.1056/NEJMoa2109682
WEBAug 4, 2021 · REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among...
DA: 93 PA: 40 MOZ Rank: 69
-
Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab…
https://newsroom.regeneron.com/news-releases/news-release-details/phase-3-trial-shows-regen-covtm-casirivimab-imdevimab-antibody/
WEBMar 23, 2021 · REGEN-COV (casirivimab with imdevimab) is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987) that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron's proprietary VelocImmune ® and VelociSuite ® technologies.
DA: 52 PA: 90 MOZ Rank: 70
-
Effect of Subcutaneous Casirivimab and Imdevimab Antibody …
https://jamanetwork.com/journals/jama/fullarticle/2788256
WEBFeb 1, 2022 · Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial | Infectious Diseases | JAMA | …
DA: 32 PA: 61 MOZ Rank: 23
-
Coronavirus disease (COVID-19): Casirivimab and Imdevimab - monoclonal
https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-casirivimab-and-imdevimab---monoclonal-antibody-therapy
WEBDec 9, 2021 · Home / Newsroom / Questions and answers / Coronavirus disease (COVID-19): Casirivimab and Imdevimab - monoclonal antibody therapy. 9 December 2021 | Q&A. Disclaimer: WHO has updated its recommendation on casirivimab-imdevimab since the publication of this Q&A.
DA: 59 PA: 69 MOZ Rank: 17
